Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2007 2
2008 6
2009 12
2010 15
2011 14
2012 7
2013 11
2014 14
2015 11
2016 10
2017 19
2018 14
2019 19
2020 12
Text availability
Article attribute
Article type
Publication date

Search Results

145 results
Results by year
Filters applied: . Clear all
Page 1
A common mechanism allows selective targeting of GluN2B subunit-containing N-methyl-D-aspartate receptors.
Schreiber JA, Schepmann D, Frehland B, Thum S, Datunashvili M, Budde T, Hollmann M, Strutz-Seebohm N, Wünsch B, Seebohm G. Schreiber JA, et al. Among authors: schepmann d. Commun Biol. 2019 Nov 15;2:420. doi: 10.1038/s42003-019-0645-6. eCollection 2019. Commun Biol. 2019. PMID: 31754650 Free PMC article.
Synthesis of 3-aza[4.4.3]propellanes with high σ1 receptor affinity.
Torres-Gómez H, Daniliuc C, Schepmann D, Wünsch B. Torres-Gómez H, et al. Among authors: schepmann d. Bioorg Med Chem. 2018 May 1;26(8):1705-1712. doi: 10.1016/j.bmc.2018.02.019. Epub 2018 Feb 15. Bioorg Med Chem. 2018. PMID: 29482951
Fluorinated GluN2B Receptor Antagonists with a 3-Benzazepine Scaffold Designed for PET Studies.
Szermerski M, Börgel F, Schepmann D, Haider A, Betzel T, Ametamey SM, Wünsch B. Szermerski M, et al. Among authors: schepmann d. ChemMedChem. 2018 May 23;13(10):1058-1068. doi: 10.1002/cmdc.201700819. Epub 2018 Apr 17. ChemMedChem. 2018. PMID: 29522653
Pyridine bioisosteres of potent GluN2B subunit containing NMDA receptor antagonists with benzo[7]annulene scaffold.
Zscherp R, Baumeister S, Schepmann D, Wünsch B. Zscherp R, et al. Among authors: schepmann d. Eur J Med Chem. 2018 Sep 5;157:397-404. doi: 10.1016/j.ejmech.2018.08.003. Epub 2018 Aug 4. Eur J Med Chem. 2018. PMID: 30103189
Synthesis and Pharmacological Evaluation of Enantiomerically Pure GluN2B Selective NMDA Receptor Antagonists.
Börgel F, Szermerski M, Schreiber JA, Temme L, Strutz-Seebohm N, Lehmkuhl K, Schepmann D, Ametamey SM, Seebohm G, Schmidt TJ, Wünsch B. Börgel F, et al. Among authors: schepmann d. ChemMedChem. 2018 Aug 10;13(15):1580-1587. doi: 10.1002/cmdc.201800214. Epub 2018 Jul 4. ChemMedChem. 2018. PMID: 29806151
Synthesis, Receptor Affinity, and Antiallodynic Activity of Spirocyclic σ Receptor Ligands with Exocyclic Amino Moiety.
Bergkemper M, Kronenberg E, Thum S, Börgel F, Daniliuc C, Schepmann D, Nieto FR, Brust P, Reinoso RF, Alvarez I, Wünsch B. Bergkemper M, et al. Among authors: schepmann d. J Med Chem. 2018 Nov 8;61(21):9666-9690. doi: 10.1021/acs.jmedchem.8b01183. Epub 2018 Oct 24. J Med Chem. 2018. PMID: 30350997
Systematic variation of the benzoylhydrazine moiety of the GluN2A selective NMDA receptor antagonist TCN-201.
Schreiber JA, Müller SL, Westphälinger SE, Schepmann D, Strutz-Seebohm N, Seebohm G, Wünsch B. Schreiber JA, et al. Among authors: schepmann d. Eur J Med Chem. 2018 Oct 5;158:259-269. doi: 10.1016/j.ejmech.2018.09.006. Epub 2018 Sep 6. Eur J Med Chem. 2018. PMID: 30218911
Synthesis and pharmacological evaluation of fluorinated benzo[7]annulen-7-amines as GluN2B-selective NMDA receptor antagonists.
Thum S, Schepmann D, Reinoso RF, Alvarez I, Ametamey SM, Wünsch B. Thum S, et al. Among authors: schepmann d. J Labelled Comp Radiopharm. 2019 Jun 30;62(8):354-379. doi: 10.1002/jlcr.3718. J Labelled Comp Radiopharm. 2019. PMID: 30850991
Identification of dual Sigma1 receptor modulators/acetylcholinesterase inhibitors with antioxidant and neurotrophic properties, as neuroprotective agents.
Rui M, Rossino G, Coniglio S, Monteleone S, Scuteri A, Malacrida A, Rossi D, Catenacci L, Sorrenti M, Paolillo M, Curti D, Venturini L, Schepmann D, Wünsch B, Liedl KR, Cavaletti G, Pace V, Urban E, Collina S. Rui M, et al. Among authors: schepmann d. Eur J Med Chem. 2018 Oct 5;158:353-370. doi: 10.1016/j.ejmech.2018.09.010. Epub 2018 Sep 8. Eur J Med Chem. 2018. PMID: 30223122
Optimization of the metabolic stability of a fluorinated cannabinoid receptor subtype 2 (CB2) ligand designed for PET studies.
Heimann D, Börgel F, de Vries H, Patberg M, Jan-Smith E, Frehland B, Schepmann D, Heitman LH, Wünsch B. Heimann D, et al. Among authors: schepmann d. Eur J Med Chem. 2018 Feb 25;146:409-422. doi: 10.1016/j.ejmech.2018.01.048. Epub 2018 Jan 31. Eur J Med Chem. 2018. PMID: 29407967
145 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback